BioSpace News Archive

- Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com - MISSISSAUGA, ON , Sept. 14, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI); (OTCQX:NRIFF), a Canadian focused healthcare company with global reach and a divers

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology powering continuous delivery of approved drugs for novel indications, announced today that Keith Darragh has joined the company as Chief Financial Officer, effective immediately.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick G. LePore to serve as a director of the Company, effective as of September 10, 2020.

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), today announced that Caelum Biosciences, Inc. (“Caelum”), in collaboration with Alexion Pharmaceuticals, Inc. (“Alexion”), initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101,

New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade

Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapy, SIR-Spheres® Y-90 resin microspheres, is pleased to report that positive trial data from the NASIR-HCC Study was reported by Professor Bruno Sangro at the International Liver Cancer Association Virtual Conference (ILCA) on September 13, 2020.

Qualtrics, the creator of the experience management (XM) category, today announced a partnership with Safe & Reliable Healthcare (S&R), a leading provider of patient safety and high reliability technologies and services to more than 700 healthcare organizations.

Viracta Therapeutics, Inc. (“Viracta” or the “Company”), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as Chairman of its Board of Directors (the “Board”)

Aegea Biotechnologies’ New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker Technology Advances in the Global XPRIZE Competition Seeking “Faster, Cheaper, and Easier-to-Use COVID-19 Testing Methods at Scale” [14-September-2020] SAN DIEGO , Sept. 14, 2020 /PRNewswire/ -- Aegea Biotechnologies, Inc. ( www.aegeabiotech.com , “Aegea”)

Can It Industries, FL, will provide OWC with its distribution channels from North America through South America while seeking for a medical-grade cannabis-infused manufacturing facility with international exporting licenses